Search | Clinical Trials Finder

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Interventions: Clofarabine; Drug
Lead sponsor: New York Medical College; Other
Eligibility: Up to 30 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Vallhala, New York

Conditions: Obesity, Venous Thrombosis, Anticoagulants
Interventions: Enoxaparin 0.5 mg/kg once daily; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Kidney Diseases
Interventions: prednisone; Drug
Lead sponsor: Florida Hospital Transplant Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Lung Cancer
Interventions: cisplatin, tirapazamine, vinorelbine tartrate; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 42
States / cities: Los Angeles, California • Oakland, California • Orange, California + 35 more

Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions: Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide, Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 56 Years and older
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: Scottsdale, Arizona • Bardstown, Kentucky • Albuquerque, New Mexico + 3 more

Conditions: Phase 1, SAR445877, FOlfox6, Bevacizimab, First Line Treatment, Metastatic Colorectal Cancer (CRC), Microsatellite Stable
Interventions: SAR445877, FOLFOX6, Bevacizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: Influenza Virus Vaccine USP Trivalent Types A and B; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 44
States / cities: Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 38 more

Conditions: Pancreatic Neoplasms
Interventions: gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin; Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Meningococcal Immunisation, Healthy Volunteers
Interventions: Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine, Placebo, MenABCYW conjugate vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,215 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 46
States / cities: Birmingham, Alabama • Guntersville, Alabama • Tempe, Arizona + 36 more

Conditions: Pancreatic Cancer
Interventions: capecitabine, gemcitabine, docetaxel; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Neuropathies
Interventions: SSR180575, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Lung Cancer
Interventions: Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Tetanus, Diphtheria, Pertussis, Whooping Cough
Interventions: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®), Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 11 Years to 12 Years
Enrollment: 423 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 8
States / cities: Sacramento, California • Bardstown, Kentucky • Woburn, Massachusetts + 5 more

Conditions: Breast Cancer
Interventions: XRP9881; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Pleural Mesothelioma, Non-small Cell Lung Cancer
Interventions: THOR-707, Pembrolizumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Tonsillitis, Pharyngitis
Interventions: Telithromycin, Penicillin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 13 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Heart Failure
Interventions: Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 1,587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 79
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more

Conditions: Depressive Disorder, Major
Interventions: saredutant (SR48968), paroxetine, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Phenylketonuria
Interventions: SAR444836; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Leukemia, Chronic Lymphocytic Leukemia
Interventions: Oral Clofarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 117
States / cities: Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more

Conditions: End Stage Renal Disease
Interventions: Rabbit Antithymocyte globulin, Daclizumab; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Myotonic Dystrophy
Interventions: SAR446268; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 10 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 5
States / cities: Gainesville, Florida • Tampa, Florida • New York, New York + 2 more

Search by objective public record fields.

Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL

Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT

A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids

Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.

Dose-effect of SSR180575 in Diabetic Neuropathy

Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer

Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents

Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults

Warfarin and Antiplatelet Therapy in Chronic Heart Failure

An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists

A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1